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INTRODUCTION
Folic acid has a high affinity with folate receptor (FR) and
is known to be a cellular membrane glycoprotein with a mo-
lecular weight of approximately 38-40 kDa (1); it shows a
different binding affinity for folic acid in many types of tumors.
Drug delivery systems containing anti-cancer agents have
recently received much attention due to their unique accu-
mulation behavior at folate-positive tumor sites (2, 3). Folic
acid binds to the folate receptors at cell surfaces with a very
high affinity (Kd=-1 nM), and it is internalized by receptor-
mediated endocytosis (4). Additionally, folate receptor has
been associated with the parameters of biological aggressi-
veness in different cancers. Folate receptor was over-expressed
to a large degree in ovarian neoplasmas that had a high his-
tological grade, advanced stage, and serious histology. A mul-
tiple comparison analysis showed that the folate receptor ex-
pression of stage IV and omental metastases was significantly
higher than that in early stage disease (5). High frequencies
of receptor overexpression have been found in many types of
tumors, including ovarian, endometrial, colorectal, breast,
lung, renal cell carcinomas, brain metastases derived from
epithelial cancers, and neuroendocrine carcinomas (6). So this
receptor has been recognized as a tumor marker, and folate
has been conjugated with anti-cancer drugs or liposomes for
tumor targeting.
The main condition of radio-labeled conjugates is needed
some characteristics such as binding specificity to ligand,
nontoxicity, and high water solubility with adequate circu-
lating time into blood. Bi-functional Poly (ethylene glycol)
is generally a very hydrophilic molecule, and it helps achieve
a long circulation time. A wide range of targeting moieties
such as galactose, folate, cell adhesive peptides, epidermal
growth factor, and transferrin have been directly conjugated
onto the distal end of the PEG chain (7). Folate modified
PEG selectively binds with tumor cells and this leads to recep-
tor-mediated endocytosis (8). The other amine group and
the flexibility of Jeffamine have the possibility of being labeled
with  99mTc. Thus, we tried to molecularly target tumors and
obtain their in vivo images by using bi-functional PEG.
In this study, PEG-folate, which can specifically bind to
tumor, was conjugated and was then labeled with 99mTc. We
analyzed the flow cytometric data and fluorescence images
that depended on the degree of the folate receptor expression
by using PEG-folate-FITC in vitro. We performed experi-
ments that showed cellular uptake of the radio-labeled con-
jugate. For imaging an animal model, we first tested the label-
ing efficiency of 99mTc PEG-folate and its stability in human
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Folate Receptor Targeted Imaging Using Poly (ethylene glycol)-folate:
In Vitro and In Vivo Studies
The aim of this study was to ascertain the folate receptor (FR) targetability by an in
vitro study and to acquire FR-targeted images in vivo models by using synthetic
folate conjugates. PEG-folate was synthesized and labeled with 
99mTc and fluores-
cein isothiocynate (FITC). Cell uptake studies were carried out in KB cells (FR-posi-
tive) and A549 cells (FR-negative) using FITC- and the 
99mTc-labeled conjugates.
The radiolabeled conjugate was intravenously injected to KB tumor xenografted
mice. After it was injected, gamma images were recorded at 30 min, 1, 2, 3 and 4
hr. Cell uptake studies showed a difference between the KB cells and the A549 cells
by flow cytometry analysis and gamma counting. On in vivo images, the tumor-to-
normal muscle ratio was greater than 4. It ascertained that the PEG-folate conju-
gate specifically binds to the FR expressed on tumor cells in vitro. Moreover, it was
possible to acquire the FR-targeted gamma images using PEG-folate conjugates
in tumor models.
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serum. Gamma camera images were acquired by using FR-
positive mice models.
MATERIALS AND METHODS
Preparation of PEG-folate conjugate
The carboxylate group of folic acid was activated by N-
hydroxysuccimide (NHS) and dicyclohexylcarbodiimide
(DCC) (9). Briefly, folic acid (0.11 g, 250  M) and triethy-
lamine dissolved in dimethylsulfoxide (DMSO, 2 mL) were
reacted with NHS (0.057 g, 500  M) and DCC (0.1 g, 500
M) at room temperature for 16 hr (folic acid: NHS: DCC
molar ratio= 1:2:2).
The precipitate was removed by filtration (0.22  m). The
activated folic acid was reacted with 0.5 g of Jeffamine (NH2-
PEG-NH2, MW: 4000) that was dissolved in 5 mL of DMSO.
The reaction was performed under a nitrogen atmosphere at
room temperature for 4 days. The supernatant was diluted
with deionized water, dialyzed (MWCO 3500, Spectrum)
against deionized water (7-8 times) and then it was freeze-
dried. The structure of the PEG-folate conjugate in DMSO-
d6 was determined by 1H-NMR. 1H-NMR was performed
on a 400 MHz apparatus (Jeol, Tokyo, Japan) and the results
were analyzed by MestRe-C 2.3a. PEG-folate was dissolved
in borate buffer (0.05 M, pH 8.3). Fluorescein isothiocyanate
(0.005 g dissolved in DMSO anhydrous) was slowly added
to the buffer and the mixture was gently stirred at room tem-
perature for 4 hr. The FITC-PEG-folate was dialyzed and
then freeze-dried.
Flow cytometric analysis 
In order to investigate selective cellular uptake of PEG-
folate via folate-receptor-mediated endocytosis, KB cells and
A549 cells (1×105) were incubated in culture medium that
lacked folic acid for 24 hr. The cells were next treated with
PEG-FITC, PEG-folate-FITC or PEG-folate-FITC with folic
acid for 1 hr, and the cells were washed three times with PBS
and harvested using 500  L of PBS with BSA. Finally we
analyzed the cells by flow cytometry (FACcan, Beckton-
Dickinson, CA, U.S.A.) of the cells.
Fluorescence microscopy study
Collagen coated cover glasses (Iwaki, Tokyo, Japan) were
placed in the wells of 24-well plates. KB cells and A549 cells
were then seeded at a density of 1×104 cells/well and they
were allowed to incubate in culture medium that had no
folic acid for 24 hr. After 24 hr, the cells were treated with
50  M PEG-folate-FITC for 1 hr. For the free folate compe-
tition studies, 1 mM folic acid was added to the incubation
medium. After washing three times with PBS, the cell-asso-
ciated fluorescent images were viewed by fluorescence micro-
scopy (Axiovison plus II, Zwiss, Jena, Germany).
Radiolabeling with 
99mTc
PEG-folate was dissolved in distilled water (5  g/ L). Stan-
nous chloride was dissolved in 0.02 N HCl (0.2  g/ L, w/v).
Two hundred micro liters of PEG-folate was mixed with 10
L of stannous chloride solution in a vial at room tempera-
ture. Labeling was carried out by adding 37 MBq (1 mCi)
sodium 99mTc pertechnetate to the above mixture, and this
was gently shaken. The 99mTc pertechnetate was eluted from
a technetium generator in our hospital (Daiichi Radioiso-
tope Laboratories, Ltd. Tokyo, Japan). The mixture was allow-
ed to react for a further 30 min, with shaking from time to
time.
The stability of 99mTc PEG-folate was determined by ITLC
and with using ITLC-sg strips (Gelman Sciences, NY, U.S.A.)
as the stationary phase, and saline was used as the mobile
phase and the stability of 99mTc PEG-folate was determined
at 10 and 30 m and at 1, 2, 3, 6 and 16 hr by using a TLC
scanner (Bioscan, Washington, D.C., U.S.A.). The stability
in the serum was tested in 0.5 mL of human serum that was
added to 200  L of radiolabeled conjugate, and the mixture
was reacted in a 37℃ water bath. The stability was deter-
mined at 10 m and 30 m, and at 1, 2, 3, 6 and 16 hr.
Labeling efficiency (%)=(Total count-Count of free pertechne-
tate)/Total count×100
Cellular uptake of radiolabeled conjugates
KB cells and A549 cells (1×106) were incubated in the
absence of folic acid in culture medium for 24 hr. After 24
hr of incubation, the cells were treated with 99mTc PEG-folate,
99mTc PEG or 99mTc PEG-folate with folic acid for 30 min,
and then the cells were washed three times with 1× HBSS
and harvested. Finally, we measured the CPM by gamma
counter (Cobra II PACKARD, MN, U.S.A.) of the cells and
counted the number of cells. The method and concentration
were same as in the in vivo imaging study, and the radio-activ-
ity of mixture was 7.4 MBq (200  Ci/500  L).
In vivo modeling
All the animal experiments were approved by the Chon-
buk National University School of Medicine Committee, and
they were performed in accordance with their guidelines.
Female athymic nude mice weighing 16-18 g each (4-5 wks,
Japan SLC, Inc., Tokyo, Japan) were placed on a folate-free
murine diet (Dyets, PA, U.S.A.) from arrival (day 0) to day
15. The animals were inoculated subcutaneously with sus-
pended KB cells (1×107/0.1 mL) in the left thigh region on
day 16 (10-12). The radiotracer studies were carried out 3Folate Receptor Targeted Imaging Using PEG-folate 407
weeks after KB cell implantation and at a total of 5 weeks
after initiation of the folate-free diet. 
Imaging of the radiolabeled conjugate
After sedating the mice with ketamine mixed with xyla-
zine, 99mTc PEG-folate was administered intravenously via a
tail vein to the animals. We then performed scintigraphy and
recorded the 30 min, 1, 2, 3 and 4 hr images by using E-
CAM camera (SIEMENS, NY, U.S.A.). The camera was equ-
ipped with a 3 mm pinhole collimator, the window setting
was 140 keV and the width was 20%. The static images were
stored in a 512×512 matrix size and the acquisition times
were 180 sec. 99mTc PEG-folate and free folic acid (10  M)
were co-injected intravenously via a tail vein (n=3) to block
the receptor-mediated uptake of the radiotracer. After admin-
istration, we acquired the gamma camera images in the same
way as above. The scintigraphic results were analyzed by
drawing the regions of interest (ROI) on the lesions and com-
paring them to the normal thigh muscle.
Statistical analysis
The t-test was applied for statistical analyses. The level of
significance was p values<.05 (two sided). Calculations were
performed using commercial (SPSSWIN 12.0) software.
RESULTS
Preparation of PEG-folate conjugate
Folic acid has two  - and  -carboxylic acids, but  -car-
boxylic acid is more selectively activated due to its higher
reactivity. The terminal carboxylic acid of folic acid was sub-
sequently activated by DCC/NHS, and it reacted with the
primary amine group of PEG. 
The conjugate was characterized by 1H NMR spectroscopy
as shown in Fig. 1. It is apparent that the spectrum of the
conjugate contains signals originating from both folic acid
and the PEG. The signal at 3.7 ppm corresponds to the pro-
ton of the PEG (-CH2-), the signals at 6.7 and 7.6 ppm cor-
respond to the para-aminobenzoic acid (PABA) from the
folate, and the signal at 8.7 ppm corresponds to the pteri-
dine moiety proton from the folate. The yield of PEG-folate
was 75%.
Flow cytometric analysis and cellular uptake
In order to investigate the selective targeting ability of
PEG-folate for the FRs on the cell, KB cells and A549 cells
were employed as FR-positive cancer cells and FR-negative
cancer cells, respectively. As shown in Fig. 2, the results of
flow cytometry of the KB cells show a greater cellular uptake
of PEG-folate-FITC than that of PEG-FITC or the PEG-
folate-FITC added folic acid when folic acid was absent in
the culture medium (Fig. 2A). However, there was no dif-
ference in the A549 cells between PEG-folate-FITC and the
PEG-FITC (Fig. 2B). 
Fluorescence image analysis of cells
The extent of the cellular uptake of PEG-folate in KB cells
Fig. 1. 1H NMR spectra of PEG (Jeffamine) and the folate-PEG conjugate.
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Fig. 2. Flow cytometric analysis of the KB (A) cells and A549 (B)
cells treated with PEG-FITC (thick black line), PEG-folate-FITC
(thin black line), and PEG-folate-FITC added folic acid (gray) in
the culture media without folic acid.
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Fig. 3. Fluorescent microscopic pictures of KB cells with folate-PEG-FITC when folic acid was absent (A, D), and present in the culture media
(B, E) and the A549 cells with folate-PEG-FITC when folic acid was absent (C, F).
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Fig. 4. ITLC chromatography of 
99mTc PEG-folate (A), labeling effi-
ciency of 
99mTc PEG-folate (B), and the stability of 
99mTc PEG-folate
in human serum (C).
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C(Fig. 3A, D) was significantly higher than in the A549 cells
(Fig. 3C, F) when folic acid was absent in the culture medium.
Further, there was no cellular uptake in the KB cells when
folic acid was added in the culture medium (Fig. 3B, E). This
result directly indicates that the PEG-folate was taken up by
a FR-mediated endocytosis process, in accordance with the
FACS results.
Labeling efficiency and stability
In the result of the ITLC-SG chromatographic strips, with
saline as the mobile phase, labeling efficiency was shown
approximately above 98% and the stability of radiolabeled
conjugates was at least 95% until 6 hr in saline (Fig. 4A, B).
Therefore, radiolabeled PEG-folate is very stable until 6 hr.
Also, the result of the stability test in human serum showed
a 90.6% yield until 16 hr (Fig. 4C).
Cellular uptake of 
99mTc PEG-folate
In order to determine whether the cellular uptake of radio-
labeled conjugate depends on the folate receptor, KB cells
and A549 cells were treated with radiolabeled PEG-folate
and competition studies were carried out for the KB cells
with using radiolabeled PEG and PEG-folate added folic
acid. The result was that the KB cells showed higher levels
of the 99mTc CPM of PEG-folate than did the A549 cells (Fig.
5A). The 99mTc CPM of the PEG or the PEG-folate added
folic acid (Fig. 5B) showed lower levels than did the 99mTc
CPM of PEG-folate in the KB cells. Especially, the cellular
uptake between PEG-folate and PEG-folate with folic acid
showed a significant difference.
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Fig. 6. Representative images of a mouse treated with 
99mTc PEG-
folate (A) and the competition images with folic acid (B).
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AImage analyses
The gamma camera image of 99mTc PEG-folate (11 MBq/
300  L) via tail vein injection demonstrated receptor medi-
ated uptake. After administration of 99mTc PEG-folate, the
images were recorded at 30 min, 1, 2, 3 and 4 hr. Until 4 hr,
the images especially showed specific binding to the tumor
and strong uptake in comparison with normal muscle (Fig. 6).
Moreover, the tumor-to-normal muscle ratio reached 4.3 at
4 hr (Fig. 7). In the competition study, the tumor uptake was
blocked by the co-injection of free folic acid, and the image
indicates our conjugate is not taken up via the folate recep-
tor for tumor localization, and the tumor to normal muscle
ratio was under 1.2 at 4 hr.
DISCUSSION
We radiolabled PEG-folate with 99mTc to target the FRs
with relative stability, and this was able to localize and detect
the regions with FR overexpression. The results of this study
demonstrated that 99mTc PEG-folate was taken up by a FR-
mediated endocytosis process. Most of the current studies
about folate have been conducted for drug delivery systems
(DDSs), and few studies have shown possibility of PEG-folate
as an imaging agent for diagnostic imaging (13-16). The sig-
nificance of this study is that we proved the targetability of
PEG-folate conjugates to FRs on cells through in vitro and
in vivo studies with using bifunctional PEG.
To synthesize folate with a PEG chain, the  - and  -car-
boxylic groups at the end of folic acid should be activated
by DCC/NHS chemistry. However, it is known that the  -
carboxylic acid was primarily conjugated due to its higher
reactivity. When activated folic acid is conjugated with PEG,
it becomes hydrophilic and the circulation time is increased
by PEG. The circulation time depends on the molecular
weight of PEG, and it is well known that if a wide range of
targeting moieties were conjugated directly to the distal end
of the PEG chain, the circulation time is increased. From the
standpoint of targeting, it is highly desirable to directly con-
jugate a targeting ligand to the PEG end group, which would
facilitate receptor-mediated endocytosis of the PEG modi-
fied complexes (17-20). For these reasons, synthesis using
folate and PEG has the possibility to be applied to nuclear
imaging of the tumor biology of FR positive tumor cells and
for following-up the therapeutic effect and prognosis.
The result of fluorescence microscopy of the KB cells clearly
indicated that the uptake of PEG-folate significantly increased
in the folate free medium compared with that of the A549
cells, and the competition with free folic acid blocked the
cell uptake of PEG-folate in the KB cells. These facts can be
confirmed by the results of the cellular uptake of radiolabeled
conjugates. These results confirmed the PEG-folate entered
into the KB cells through the folate receptor endocytosis path-
way. Folic acid is taken up via the FR on the cell membrane
and it acts as a precursor of tetrahydrofolate in the nucleus
(21). The result of strong uptake of the cellular nucleus in
this study demonstrates that the PEG-folate conjugate moves
through the nuclear membrane (Fig. 3).
Functional groups such as -COOH, -OH, -NH2, and -SH
can form coordinate covalent bonds with 99mTc (22, 23). Gen-
erally, PEG can’t be radiolabeled with 99mTc without using a
chelator. In this study, we infer that 99mTc forms coordinate
covalent bonds with the amine group of PEG (Jeffamine),
which specifically serves as a chelating moiety. 
Studies related to folate as an imaging agent have used
EC20, MAG3 and DTPA for chelation with 99mTc, and the
folate conjugate using PEG was also labeled with 99mTc using
DTPA (24-26). Yet we directly labeled the PEG-folate with
99mTc, and the yield of the radiolabeled conjugate was over
95% until 6 hr in vitro and it was 90% until 6 hr in serum
conditions. The formation of a coordinate covalent bond bet-
ween 99mTc and the amine group at the end of PEG, and the
relatively large molecular weight and flexibility of PEG are
considered the characteristics that contributed to stable label-
ing efficiency.
On the in vivo study, we succeeded in performing tumor
targeted nuclear imaging using 99mTc PEG-folate in mice,
and the tumor-to-normal muscle ratio was approximately 4.
On the competitive study, binding of 99mTc PEG-folate was
blocked by the co-injection of free folic acid, so the images
didn’t show uptake in tumor region and the tumor to nor-
mal muscle ratio was approximately 1. These results mean
that uptake of PEG-folate was inhibited by folic acid and
our conjugate specifically binds to FR and this appropriates
to the results of the cellular uptake studies.
In summary, we were able to stably label PEG-folate with
99mTc and we confirmed that our conjugate specifically binds
to FR. On the results of flow cytometric analysis, fluorescence
microscopy study and measurement of 99mTc CPM, we con-
firmed that PEG-folate was endocytosed via the FR in vitro.
Especially, the CPM of 99mTc PEG-folate was much higher
than that of 99mTc PEG, and the variation was almost 60%.
Moreover, we applied our conjugates in vivo, and the results
of the images were well accorded with the results of the cellu-
lar uptake experiments. In conclusion, we could specifically
trace the FR on the cell surface with using the PEG-folate
conjugates in the in vitro and in vivo studies.
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